Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies

Glasdegib is approved for treating acute myeloid leukemia in elderly patients at 100 mg once daily in combination with low‐dose cytarabine. Exposure‐efficacy analysis showed that the survival benefit of glasdegib was not glasdegib exposure‐dependent. The relationship between glasdegib exposure and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz‐Garcia, Ana, Shaik, Naveed, Lin, Swan, Jamieson, Catriona, Heuser, Michael, Chan, Geoffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Exposure‐Response
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891441/
https://www.ncbi.nlm.nih.gov/pubmed/32974950
http://dx.doi.org/10.1002/jcph.1742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891441/
https://www.ncbi.nlm.nih.gov/pubmed/32974950
http://dx.doi.org/10.1002/jcph.1742

Ejemplares similares